All In MedTech

Device Trial Radar · NCT04044248

TIPS Plus Transvenous Obliteration for Gastric Varices

Single Center Prospective Pilot Study of Combined Transjugular Intrahepatic Portosystemic Shunt Creation Plus Transvenous Obliteration for the Treatment of Gastric Varices

Last checked: Nov 19, 2026Latest source record: Nov 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

8

Actual

Start

Apr 4, 2019

Primary completion

Jun 18, 2024

Study completion Jun 18, 2024

Sponsor

Lead sponsor
University of Illinois ChicagoAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 5, 2019

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 18 years

Summary

As written by the sponsor on the registry.

Variceal hemorrhage (VH) from gastric varices (GVs) results in significant morbidity and mortality among patients with liver cirrhosis. In cases of acute bleeding, refractory bleeding, or high risk GVs, the transjugular intrahepatic portosystemic shunt (TIPS) creation and transvenous variceal obliteration procedures have used to treat GVs. While these techniques are effective, each is associated with limitations, including non-trivial rebleeding and hepatic encephalopathy rates for TIPS and aggravation of esophageal varices, development of new or worsening ascites, and formation of difficult to treat ectopic varices for transvenous obliteration. Increasingly, however, TIPS and transvenous obliteration are viewed as complimentary procedures that can be combined to reduce bleeding risk and ameliorate sequelae of portal hypertension. Yet, despite a strong mechanistic basis for their combination, there are few studies investigating the combined effectiveness of TIPS plus transvenous obliteration. Thus, the aim of this single center prospective pilot study is to assess the effectiveness and safety of combined TIPS creation plus transvenous obliteration for the treatment of GVs, with the overall goal of improving the clinical outcomes of patients with VH related to GVs. The work proposed could lead to important advances in the treatment of bleeding complications due to liver cirrhosis.

Conditions

  • Cirrhosis, Liver
  • Hypertension, Portal
  • Esophageal and Gastric Varices
  • Bleeding Gastric
  • Encephalopathy

Interventions

  • TIPS-obliterationDevice

    Transjugular intrahepatic portosystemic shunt (TIPS) decompression of portal hypertension coupled with transvenous obliteration of gastric varices (GVs).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Endoscopic gastric varices eradication rateTime frame: 6-months
  2. Endoscopic esophageal varices aggravation/resolution rateTime frame: 6-months
  3. Imaging gastric variceseradication rateTime frame: 1-year

2 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Illinois at Chicago

    Chicago, Illinois

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.